The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
AM23-MN-03-O - AM23-MN-03-O: Hyperhemolysis Syndrome: Recognition and Current Management Strategies of a Potentially Fatal Transfusion Complication (Enduring)
Hyperhemolysis syndrome (HHS) is an uncommon but life-threatening complication of transfusion that classically occurs in patients with sickle cell anemia but may also be seen in patients without hemoglobinopathies. Recognition of HHS is critical for appropriate management but can be challenging. The first speaker of this session—a transfusion medicine specialist—will present a systematic review of published HHS cases, articulating the epidemiological, clinical, and laboratory features of HHS and patient outcomes, including in obstetric patients. While evidence-based guidelines for managing HHS are lacking, varied and emerging strategies have been described, such as corticosteroids, intravenous immune globulin, eculizumab, and tocilizumab. The second speaker of this session—a pediatric hematologist-oncologist and transfusion medicine specialist—will present the proposed pathophysiological mechanisms of HHS and an appraisal of current management strategies.
Learning Objectives:
Define the diagnostic and clinical features of hyperhemolysis syndrome (HHS)
Examine the transfusion considerations in patients with acute HHS or a history of HHS
Discuss the role of immunomodulatory therapies for refractory HHS
Moderator(s):
Laura
Stephens,
MD,
Associate Professor; Associate Medical Director,
University of California San Diego
Speaker(s):
Ross
Fasano,
MD,
Associate Professor,
Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, GA, USA; Center for Transfusion and Cellular Therapies, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA
Jeremy
Jacobs,
MD, MHS,
Special Coagulation Fellow,
Department of Laboratory Medicine, Yale School of Medicine
Disclosures
Ross Fasano, MD:
No relevant disclosure to display
Jeremy Jacobs, MD, MHS:
No financial relationships to disclose
Laura Stephens, MD:
Global Blood Therapeutics, Inc. (Dr. Fasano): Consultant/Advisory Board (Terminated, July 10, 2022)
All relevant financial relationships have been mitigated.
By completing the evaluation, you are attesting to watching the presentation in its entirety. A certificate will be immediately provided after submission.
Credits Available
AM23-MN-03-O: Hyperhemolysis Syndrome: Recognition and Current Management Strategies of a Potentially Fatal Transfusion Complication (Enduring) Evaluation